BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 37185436)

  • 21. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
    Siewe N; Friedman A
    PLoS One; 2022; 17(1):e0262453. PubMed ID: 35015785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
    Zorko NA; Ryan CJ
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):986-996. PubMed ID: 34035459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
    Gervaso L; Ciardiello D; Oliveira RA; Borghesani M; Guidi L; Benini L; Algeri L; Spada F; Zampino MG; Cella CA; Fazio N
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
    Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
    Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
    Kwan EM; Spain L; Anton A; Gan CL; Garrett L; Chang D; Liow E; Bennett C; Zheng T; Yu J; Dai C; Du P; Jia S; Fettke H; Abou-Seif C; Kothari G; Shaw M; Parente P; Pezaro C; Tran B; Siva S; Azad AA
    Eur Urol; 2022 Mar; 81(3):253-262. PubMed ID: 34493414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review.
    Li N; Wan Z; Lu D; Chen R; Ye X
    Front Immunol; 2022; 13():1088683. PubMed ID: 36703977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
    Thomas J; Leal A; Overman MJ
    Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is There a Role for Immunotherapy in Prostate Cancer?
    Rizzo A; Mollica V; Cimadamore A; Santoni M; Scarpelli M; Giunchi F; Cheng L; Lopez-Beltran A; Fiorentino M; Montironi R; Massari F
    Cells; 2020 Sep; 9(9):. PubMed ID: 32911806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.
    Kim TJ; Koo KC
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
    Sena LA; Fountain J; Isaacsson Velho P; Lim SJ; Wang H; Nizialek E; Rathi N; Nussenzveig R; Maughan BL; Velez MG; Ashkar R; Larson AC; Pritchard CC; Adra N; Bryce AH; Agarwal N; Pardoll DM; Eshleman JR; Lotan TL; Antonarakis ES
    Oncologist; 2021 Feb; 26(2):e270-e278. PubMed ID: 33215787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
    Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy.
    Yang Y; Meng WJ; Wang ZQ
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):69. PubMed ID: 37114536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond.
    Cohen R; Rousseau B; Vidal J; Colle R; Diaz LA; André T
    Target Oncol; 2020 Feb; 15(1):11-24. PubMed ID: 31786718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer.
    Staniszewska M; Iking J; Lückerath K; Hadaschik B; Herrmann K; Ferdinandus J; Fendler WP
    Nucl Med Biol; 2021; 96-97():101-111. PubMed ID: 33866131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches.
    Marshall CH; Antonarakis ES
    Cancer Treat Res Commun; 2020 Jan; 23():100164. PubMed ID: 31978677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
    Laccetti AL; Subudhi SK
    Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.